Enlivex Therapeutics Ltd
Change company Symbol lookup
Select an option...
ENLV Enlivex Therapeutics Ltd
HBUV Hubilu Venture Corporation
LMNL Liminal BioSciences Inc
NXTD NXT-ID Inc
RIOT Riot Blockchain Inc
HIHO Highway Holdings Ltd
CBAY Cymabay Therapeutics Inc
DTSS Datasea Inc
MOXC Moxian Inc
EDRY EuroDry Ltd
Go

Health Care : Biotechnology | Small Cap Blend
Based in Israel
Company profile

Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.

Closing Price
$5.33
Day's Change
-0.13 (-2.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.54
Day's Low
5.33
Volume
(Above Average)
Volume:
71,746

10-day average volume:
63,874
71,746

Upcoming Events

ENLV's fiscal year ends in December
There are no upcoming events for ENLV

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
May 18, 2020Q1 2020 Earnings Release-$0.07-$0.24 to -$0.24--
April 30, 2020Q4 2019 Earnings Release-$0.28-$0.25 to -$0.25--

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.